scholarly journals The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease

Oncotarget ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 2044-2052 ◽  
Author(s):  
Ling-Sai Chang ◽  
Mao-Hung Lo ◽  
Sung-Chou Li ◽  
Ming-Yu Yang ◽  
Kai-Sheng Hsieh ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Kawasaki Disease ◽  
Intravenous Immunoglobulin ◽  
Coronary Artery Lesion ◽  
Lesion Formation ◽  
Immunoglobulin Treatment ◽  
Treatment Responses

scholarly journals Lack of Association betweenCLEC5AGene Single-Nucleotide Polymorphisms and Kawasaki Disease in Taiwanese Children

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Ya-Ling Yang ◽  
Wei-Pin Chang ◽  
Yu-Wen Hsu ◽  
Wei-Chiao Chen ◽  
Hong-Ren Yu ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Kawasaki Disease ◽  
Single Nucleotide Polymorphisms ◽  
Treatment Response ◽  
Intravenous Immunoglobulin ◽  
Coronary Artery Lesion ◽  
Nucleotide Polymorphisms ◽  
Lesion Formation ◽  
Single Nucleotide ◽  
Immunoglobulin Treatment

Background. Kawasaki disease is characterized by systemic vasculitis of unknown etiology. Previous genetic studies have identified certain candidate genes associated with susceptibility to KD and coronary artery lesions. Host innate immune response factors are involved in modulating the disease outcome. The aim of this study was to investigate CLEC5A (C-type lectin domain family 5) genetic polymorphisms with regards to the susceptibility and outcome of KD.Methods. A total of 1045 subjects (381 KD patients and 664 controls) were enrolled to identify 4 tagging single-nucleotide polymorphisms (tSNPs) ofCLEC5A(rs1285968, rs11770855, rs1285935, rs1285933) by using the TaqMan Allelic Discrimination Assay. The Hardy-Weinberg equilibrium was assessed in cases and controls, and genetic effects were evaluated by the chi-square test.Results. No significant associations were noted between the genotypes and allele frequency of the 4CLEC5AtSNPs between controls and patients. In the patients, polymorphisms ofCLEC5Ashowed no significant association with coronary artery lesion formation and intravenous immunoglobulin treatment response.Conclusions. This study showed for the first time that polymorphisms ofCLEC5Aare not associated with susceptibility to KD, coronary artery lesion formation, and intravenous immunoglobulin treatment response in a Taiwanese population.

scholarly journals Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease　– A Multicenter Retrospective Study –

2016 ◽  
Vol 80 (11) ◽  
pp. 2376-2381 ◽  
Author(s):  
Yoshiaki Okuma ◽  
Kenji Suda ◽  
Hideyuki Nakaoka ◽  
Yasuhiro Katsube ◽  
Yoshihide Mitani ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Coronary Artery ◽  
Kawasaki Disease ◽  
Intravenous Immunoglobulin ◽  
Coronary Artery Lesion ◽  
Tenascin C

scholarly journals ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease

2011 ◽  
Vol 13 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Y Onouchi ◽  
Y Suzuki ◽  
H Suzuki ◽  
M Terai ◽  
K Yasukawa ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Kawasaki Disease ◽  
Coronary Artery Lesion ◽  
Lesion Formation

A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease

2015 ◽  
Vol 25 (6) ◽  
pp. 1182-1190 ◽  
Author(s):  
Xi Yang ◽  
Guiying Liu ◽  
Yaqian Huang ◽  
Stella Chen ◽  
Junbao Du ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Coronary Artery ◽  
Body Temperature ◽  
Kawasaki Disease ◽  
Confidence Interval ◽  
Intravenous Immunoglobulin ◽  
Odds Ratio ◽  
Meta Analysis ◽  
Coronary Artery Lesions ◽  
Immunoglobulin Treatment

AbstractObjectiveTo determine the optimal drug therapy for intravenous immunoglobulin-resistant Kawasaki disease.MethodsStudies regarding drug therapy for intravenous immunoglobulin-resistant Kawasaki disease were selected from medical electronic databases including PubMed, Medline, Elsevier, and Springer Link. The effectiveness in terms of temperature recovery and coronary artery damage was compared between a second intravenous immunoglobulin treatment and glucocorticosteroid treatment for children with intravenous immunoglobulin-resistant Kawasaki disease using meta-analysis with Review Manager 5.3 software. Indices to evaluate the effects were body temperature, biomarker levels, and coronary artery lesions detected by echocardiography. Results are reported as relative risks or odds ratio with a 95% confidence interval and p<0.05.ResultsMeta-analysis included 52 patients in the second intravenous immunoglobulin treatment group and 75 patients in the glucocorticosteroid treatment control group from four studies that met our inclusion criteria. Temperatures of patients who received glucocorticosteroid treatment were effectively controlled compared with those who received a second intravenous immunoglobulin treatment (relative risk=0.73, 95% confidence interval: 0.58–0.92, p=0.007). There were no differences, however, in the incidence of coronary artery lesions between the two groups (odds ratio=1.55, 95% confidence interval: 0.57–4.20, p=0.39).ConclusionsGlucocorticosteroids are more effective in controlling body temperature compared with intravenous immunoglobulin re-treatment in intravenous immunoglobulin-resistant Kawasaki disease children; however, glucocorticosteroids and intravenous immunoglobulin re-treatment showed no difference in the prevention of coronary artery lesions.

scholarly journals High risk of coronary artery aneurysm in Kawasaki disease

Rheumatology ◽  
2020 ◽  
Author(s):  
Maria Mossberg ◽  
Aladdin J Mohammad ◽  
Fredrik Kahn ◽  
Mårten Segelmark ◽  
Robin Kahn
Keyword(s):  
Coronary Artery ◽  
High Risk ◽  
Kawasaki Disease ◽  
Intravenous Immunoglobulin ◽  
Demographic Data ◽  
Artery Aneurysm ◽  
Heart Association ◽  
Coronary Aneurysms ◽  
Immunoglobulin Treatment ◽  
Timely Treatment

Abstract Objective Kawasaki disease (KD) is a vasculitis of unknown aetiology with a high risk of coronary aneurysms if untreated. Timely treatment with intravenous immunoglobulin decreases the risk for coronary artery aneurysms (CAA). In this study, we set out to elucidate the factors associated with the risk of developing CAA. Methods Records of all KD-diagnosed children in Skåne between 2004 and 2014 were collected and clinical and demographic data were compiled. KD is defined according to the revised American Heart Association diagnostic criteria and classified as either complete KD (cKD) or incomplete KD (iKD). Results KD was diagnosed in 77 children and CAA was found in 31% (n = 24). Children with CAA were younger compared with children without (median; 20 vs 34 months) and intravenous immunoglobulin treatment within 10 days was less likely to be received (75% vs 91%). In children presenting with iKD, 47% developed CAA compared with 21% in cKD patients. Using multivariate analysis, an association between the risk of CAA with low age in children with iKD was observed. Conclusion The risk of CAA development is disturbingly high in young children with iKD. This highlights the importance of rapid intense treatment and vigilance in infants, who are the most difficult to diagnose, in order to reduce the frequency of CAA.

scholarly journals Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High‐Risk Patients With Kawasaki Disease

2020 ◽  
Vol 9 (17) ◽  
Author(s):  
Ryusuke Ae ◽  
Joseph Y. Abrams ◽  
Ryan A. Maddox ◽  
Lawrence B. Schonberger ◽  
Yosikazu Nakamura ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Treatment Group ◽  
High Risk ◽  
Kawasaki Disease ◽  
Treatment Failure ◽  
Intravenous Immunoglobulin ◽  
Combination Treatment ◽  
Coronary Artery Abnormalities ◽  
Estimated Risk ◽  
Immunoglobulin Treatment

BACKGROUND Randomized controlled trials previously provided different conclusions about the superiority of adding corticosteroids to initial intravenous immunoglobulin treatment for the prevention of coronary artery abnormalities in patients with Kawasaki disease (KD). To further assess this issue, we analyzed large‐scale data from nationwide KD surveys in Japan, where combination treatment (corticosteroids added to initial standard intravenous immunoglobulin treatment) has become commonly used for patients at high risk for KD. METHODS AND RESULTS Standard intravenous immunoglobulin treatment and combination treatment were compared using data from time periods with and without combination treatment. Outcome measures were coronary artery abnormalities and initial intravenous immunoglobulin treatment failure. Hospitals where ≥20% of patients received combination treatment were identified, and treatment and control groups were selected via matching by age, sex, illness day at initial treatment, and KD recurrence. Matched group selection and subsequent analyses were conducted 1000 times to minimize sampling bias and potential confounders (bootstrapping). From 115 hospitals, 1593 patients with KD in the treatment group and 1593 controls were selected for each of the 1000 sample iterations. The median proportion of patients who developed coronary artery abnormalities among the treatment group and controls were 4.6% (95% CI, 3.8%–5.8%) and 8.8% (95% CI, 7.5%–10.0%), respectively: an estimated risk ratio of 0.53 (0.41–0.67). A median of 14.1% (95% CI, 12.4%–15.9%) of the patients in the treatment group and 21.7% (95% CI, 19.8%–23.4%) in the controls had treatment failure: an estimated risk ratio of 0.65 (0.56―0.75). CONCLUSIONS Combination treatment reduced coronary artery abnormality risk by an estimated 47% and treatment failure by 35%. Multiple‐dose corticosteroids may provide benefit in selected patients at high risk for KD.

scholarly journals IL-31 Associated with Coronary Artery Lesion Formation in Kawasaki Disease

PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e105195 ◽  
Author(s):  
Wan-Ning Tseng ◽  
Mao-Hung Lo ◽  
Mindy Ming-Huey Guo ◽  
Kai-Sheng Hsieh ◽  
Wei-Chiao Chang ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Kawasaki Disease ◽  
Coronary Artery Lesion ◽  
Lesion Formation

Stratified therapy for Kawasaki disease using a new scoring system to predict the response to a lower dose of intravenous immunoglobulin therapy

2021 ◽  
pp. 1-5
Author(s):  
Misa Matsuura ◽  
Daisuke Sugawara ◽  
Eishi Makita ◽  
Yuka Hirakubo ◽  
Kazuhito Nonaka ◽  
...  
Keyword(s):  
Coronary Artery ◽  
High Risk ◽  
Kawasaki Disease ◽  
Intravenous Immunoglobulin ◽  
Risk Score ◽  
Risk Group ◽  
Immunoglobulin Therapy ◽  
Low Risk ◽  
Immunoglobulin Treatment ◽  
New Scoring

Abstract Background: Several studies have reported treatment options for patients with Kawasaki disease refractory to standard immunoglobulin therapy; however, no studies have reported low-dose immunoglobulin therapy for patients with a low risk of Kawasaki disease. Methods: A total of 277 patients with Kawasaki disease were included in this study. We used Kobayashi score and our Less high-risk score to divide the patients into three groups. Patients in the high-risk group (Kobayashi score ≥ 5 points) received 2 g/kg intravenous immunoglobulin and prednisolone. Patients in the moderate-risk group (Kobayashi score < 5 points and Less high-risk score ≥ 2 points) received 2 g/kg intravenous immunoglobulin treatment. Patients in the low-risk group (Kobayashi score < 5 points and Less high-risk score < 2 points) received 1 g/kg intravenous immunoglobulin treatment. The response rate and the incidence of coronary artery lesions at 4 weeks after treatment were evaluated in each group. Results: The treatment response rates in the high-risk (n = 110), moderate-risk (n = 80), and low-risk (n = 87) groups were 74.5, 72.5, and 77.0%, respectively. Coronary artery lesions occurred in 7.3, 3.8, and 2.3% of patients in the high-, moderate-, and low-risk groups, respectively. There were no significant differences between the groups regarding treatment response or coronary artery lesion rate. Conclusion: The therapeutic response rate and the therapeutic effect of low-dose intravenous immunoglobulin in the low-risk group identified with our new scoring were satisfactory. Stratified therapies for patients with Kawasaki disease based on the scoring system may be useful.

Sign in / Sign up

Export Citation Format

Share Document